Labcorp Expands Reach with Acquisition of MAWD Pathology Group
Labcorp Holdings, Inc. LH has announced plans to acquire selected assets from MAWD Pathology Group in Lenexa, KS, focusing on its clinical and women’s health testing businesses. Both companies are dedicated to enhancing community health through exceptional laboratory services.
The deal is expected to finalize by early 2025, pending standard closing conditions. Until then, existing operations and services will remain unchanged.
Market Reaction to Labcorp’s Acquisition News
After the announcement yesterday, Labcorp’s stock saw a slight decline of nearly 1%, closing at $229.62. On a brighter note, the company’s substantial pipeline for potential acquisitions of hospitals and local laboratories indicates promising growth opportunities ahead. Labcorp’s effective strategic execution positions it as a preferred partner for health systems, utilizing science and technology to strengthen its offerings. Therefore, we anticipate continued positive market sentiment around LH stock following this news.
Labcorp’s market capitalization stands at $19.41 billion. According to the Zacks Consensus Estimate, the company’s earnings are slated to grow by 7.1%, alongside a 0.7% rise in revenues. Notably, Labcorp has surpassed earnings expectations in the last four quarters, averaging a beat of 2.87%.
Details on the MAWD Pathology Acquisition
After the acquisition, patients and healthcare professionals will gain better access to Labcorp’s high-quality laboratory services. Additionally, testing capabilities will improve in the Kansas City area and surrounding communities. MAWD Pathology Group will maintain its provision of comprehensive anatomic professional and technical pathology services. Labcorp aims to uphold and expand MAWD’s long-standing tradition of quality healthcare offerings.
Image Source: Zacks Investment Research
This latest acquisition aligns with Labcorp’s ongoing efforts to finalize deals with various local and regional health systems, improving patient and provider services.
Promising Industry Trends for Labcorp
According to a research report, the global clinical laboratory services market was valued at $233.24 billion in 2023, with a projected compound annual growth rate of 3.5% through 2030. Key growth drivers include the rising prevalence of chronic diseases and the increasing demand for early diagnostic tests. Furthermore, advancements in data management and sample processing are expected to further stimulate market growth during this period.
Recent Strategic Moves by Labcorp
Recently, Labcorp finalized its acquisition of selected outreach laboratory services from Ballad Health, aiming to enhance laboratory service access in the Appalachian region. Additionally, in November 2024, Labcorp acquired specific assets from Lab Works, an accredited independent clinical laboratory in Birmingham, AL.
Performance of LH Stock
Over the past six months, Labcorp shares have appreciated by 11.3%, significantly outperforming the industry average increase of 0.5%.
Labcorp’s Zacks Rank and Noteworthy MedTech Stocks
Currently, Labcorp holds a Zacks Rank of #3 (Hold).
In the broader medical sector, some of the top-ranked stocks include Penumbra PEN, Haemonetics HAE, and Phibro Animal Health PAHC, all with a Zacks Rank of #2 (Buy). You can view the full list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Penumbra shares have decreased by 0.1% over the last year. In the past 30 days, 2024 earnings per share estimates have risen by 2 cents to $2.81. PEN has outperformed earnings expectations in three of the last four quarters, with an average surprise of 10.54%. The last quarter resulted in an earnings surprise of 23.19%.
Haemonetics’ fiscal 2025 earnings estimates have remained steady at $4.59 over the past month. Its shares have declined by 7% in the last year, in contrast to an industry growth of 13.9%. HAE’s earnings exceeded projections in three of the last four quarters, with an average surprise of 2.82%. The last quarter yielded a 2.75% surprise.
Phibro Animal Health has seen a 1.9% upward revision in its fiscal 2025 earnings estimates, now at $1.62. Its shares skyrocketed 100% over the past year, versus a 13.9% industry increase. PAHC has beaten earnings expectations in all four recent quarters, averaging a surprise of 25.47%, with the last quarter showing a 52.17% surprise.
Discover Top Stocks for 2025
Are you interested in getting early insights on our top stock picks for 2025?
Historically, these selections have shown outstanding performance.
From 2012, when our Director of Research Sheraz Mian began managing this portfolio, to November 2024, the Zacks Top 10 Stocks achieved a gain of +2,112.6%, vastly outperforming the S&P 500’s +475.6%. As we prepare for 2025, Sheraz is analyzing 4,400 companies to identify the best 10 stocks for investment. Be sure to get the latest information when these stocks are revealed on January 2.
Get Early Access to Top 10 Stocks >>
Labcorp (LH) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report
Penumbra, Inc. (PEN) : Free Stock Analysis Report
For the full article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
